Testing blood and bone marrow samples in young leukemia patients
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial looks at blood and bone marrow samples from children and teens whose leukemia has come back or is hard to treat. The goal is to better understand the disease and guide future options for these patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be under 22 years old when you enroll
- Have a leukemia or related blood cancer that has come back or is hard to treat (specific types listed in the protocol)
- Have one of these possibilities: AML, ALL, MPAL, JMML, MDS, or related forms (including treatment-related or Down syndrome–related)
- Your team must be able to confirm the exact leukemia subtype using study rules
- You (or your parent/legal guardian) must sign informed consent, and required medical and regulatory steps must be met
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows children and young adults with Down syndrome who have survived acute leukemia (ALL or AML) to learn about their longer-term health after treatment ends. It may help families and doctors understand what health problems to watch for and how to provide better follow-up care.
This trial looks at how childhood, teen, and young adult acute myeloid leukemia (AML) changes at the genetic level and how cells respond to multiple drugs. It may help doctors understand which treatments work best and how leukemia interacts with supportive cells in the bone marrow.
This trial studies how different blood cancers and early (pre-cancer) blood conditions work, using tumor/blood tissue samples. It may help researchers learn more about disease biology for future treatments, with little to no extra risk if samples come from routine care.
This trial tests a strong chemotherapy and radiation combo followed by a donor stem cell transplant for people with aggressive blood cancers (like AML or MDS) that haven't responded to earlier treatments or came back. It aims to help prevent the cancer from returning.
This study looks at leukemia “genetic clues” using special stored samples, including cord blood saved at birth. It may help researchers better understand leukemia biology and how common mutations may show up early.
This study follows people who are newly diagnosed (and haven’t been fully treated yet) with specific leukemia or related blood disorders to help researchers learn which treatments may work best. It may help by connecting you to a larger “precision medicine” patient group for future research.
Hear when a new Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.